Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
QNCX
$0.1333
$
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Next Earnings
2026-02-25
Beta
1.238
Average Volume
Market Cap
Last Dividend
CIK
0001662774
ISIN
US22053A1079
CUSIP
22053A107
CEO
Dirk Thye
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
36
IPO Date
2019-05-09
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours | Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans. | Benzinga | 2026-02-13 01:51:11 |
| Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks | Quince Therapeutics Inc (NASDAQ: QNCX) stock is trading sharply lower Thursday after the biotech company followed up Wednesday's rally with a Form 8-K that underscores how precarious its situation is. Here's what investors need to know amid this week's volatility. | Benzinga | 2026-02-12 12:27:20 |
| Investors Purchase Large Volume of Quince Therapeutics Call Options (NASDAQ:QNCX) | Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 28,800 call options on the company. This represents an increase of 1,366% compared to the typical volume of 1,964 call options. Quince Therapeutics Stock Performance Shares of NASDAQ: QNCX opened at $0.61 on Thursday. Quince | Defense World | 2026-02-12 04:34:52 |
| Quince Therapeutics Stock Explodes 300% On Strategic Review | Quince Therapeutics Inc shares are soaring Tuesday as the company has engaged LifeSci Capital to serve as its exclusive financial advisor. | Benzinga | 2026-02-10 15:05:37 |
| Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also a. | Business Wire | 2026-02-09 16:05:00 |
| Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, the company's pivotal Phase 3 in. | Business Wire | 2026-01-29 15:10:00 |
| Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The obj. | Business Wire | 2026-01-28 16:05:00 |
| Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential | Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment. | Seeking Alpha | 2026-01-12 11:08:28 |
| Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages | Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong | Defense World | 2026-01-12 01:50:50 |
| Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Moderate Buy” from Analysts | Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one | Defense World | 2025-12-18 01:58:49 |
| Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company's pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patie. | Business Wire | 2025-12-15 08:00:00 |
| Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient's own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers i. | Business Wire | 2025-12-10 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| 8-K | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 424B5 | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| EFFECT | 2025-08-06 | 2025-08-06 | View Filing |
| 424B5 | 2025-08-05 | 2025-08-05 | View Filing |
| S-3 | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| D | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-04-30 | 2025-04-30 | View Filing |
| ARS | 2025-04-23 | 2025-04-23 | View Filing |
| DEFA14A | 2025-04-23 | 2025-04-23 | View Filing |
| DEF 14A | 2025-04-23 | 2025-04-23 | View Filing |
| PRE 14A | 2025-04-09 | 2025-04-09 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 424B5 | 2025-03-24 | 2025-03-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13G/A | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 424B5 | 2024-12-27 | 2024-12-27 | View Filing |
| EFFECT | 2024-12-27 | 2024-12-27 | View Filing |
| S-3 | 2024-12-18 | 2024-12-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13D | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 4 | 2024-09-03 | 2024-09-03 | View Filing |
| 4 | 2024-08-22 | 2024-08-22 | View Filing |
| 4 | 2024-08-21 | 2024-08-21 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| SC 13G/A | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 8-K | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| ARS | 2024-04-24 | 2024-04-24 | View Filing |
| DEFA14A | 2024-04-24 | 2024-04-24 | View Filing |
| DEF 14A | 2024-04-24 | 2024-04-24 | View Filing |
| PRE 14A | 2024-04-11 | 2024-04-11 | View Filing |
| S-8 | 2024-04-01 | 2024-04-01 | View Filing |
| 10-K | 2024-04-01 | 2024-04-01 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Heikin Ashi Strategy | 39.29% | 1.16 | 11 | 0.93 | 1.48 | 17.49 |
| Adaptive Wave | 28.17% | 1 | 1 | 0.71 | 1.2 | 6.37 |
| Donchian Channel Strategy | 26.66% | 1.01 | 20 | 0.8 | 1.4 | 4.86 |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |